Abstract
Atherosclerosis kills more patients with diabetes than all other causes combined. Aggressive reversal and treatment of dyslipidemias is the only proven prevention for coronary events in the patient with type 2 diabetes. Glycemic control with diet, oral hypoglycemic agents, and insulin, when necessary, is often only partially effective in normalizing lipid values in type 2 diabetes. Intensive treatment with lipid-regulating agents, particularly HMG-CoA reductase inhibitors, is often necessary to normalize diabetes-associated dyslipidemias. HMG-CoA reductase inhibitors are also the only agents thus far shown in prospective multicenter trials to reduce the risk of coronary events in diabetic patients.
MeSH terms
-
Administration, Oral
-
Arteriosclerosis / complications
-
Arteriosclerosis / prevention & control
-
Blood Glucose / metabolism
-
Cardiovascular Diseases / complications*
-
Cardiovascular Diseases / prevention & control
-
Coronary Disease / prevention & control
-
Diabetes Mellitus, Type 2 / blood
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / prevention & control
-
Diabetic Angiopathies / complications*
-
Diabetic Angiopathies / prevention & control
-
Diet, Diabetic
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
-
Hyperlipidemias / complications*
-
Hyperlipidemias / drug therapy
-
Hyperlipidemias / prevention & control
-
Hypoglycemic Agents / administration & dosage
-
Hypoglycemic Agents / therapeutic use
-
Insulin / administration & dosage
-
Insulin / therapeutic use
-
Lipids / blood
-
Multicenter Studies as Topic
-
Prospective Studies
-
Risk Factors
Substances
-
Blood Glucose
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Hypoglycemic Agents
-
Insulin
-
Lipids